Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics, Inc. (ALLO) is a clinical-stage biotechnology leader developing off-the-shelf CAR T cell therapies for cancer and autoimmune diseases. This news hub provides investors and industry professionals with timely updates on clinical advancements, regulatory milestones, and strategic partnerships shaping the future of allogeneic cell treatments.
Access authoritative updates on ALLO's innovative pipeline, including progress with Dagger® technology and CRISPR-engineered therapies. Our curated news collection offers:
- Press releases detailing trial results and FDA interactions
- Financial reports and earnings call summaries
- Analysis of collaborations with academic and industry partners
- Updates on manufacturing scalability and therapeutic applications
Bookmark this page for centralized access to verified information on Allogene's progress in creating accessible, next-generation cell therapies. Check regularly for developments in hematologic malignancies, solid tumor treatments, and autoimmune disease research.
Allogene Therapeutics (NASDAQ: ALLO) will present updated data from two significant clinical trials at the 2025 ASCO Annual Meeting. The first presentation features results from the completed Phase 1 TRAVERSE trial of ALLO-316, their allogeneic CAR T product targeting CD70 in renal cell carcinoma (RCC). Previous data showed promising safety and anti-tumor activity in heavily pretreated patients with advanced CD70+ RCC.
The second presentation highlights their ongoing pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL). This groundbreaking study is the first to evaluate an allogeneic CAR T product as first-line consolidation treatment. The randomized trial will enroll approximately 240 patients and aims to improve event-free survival compared to standard care.
Allogene Therapeutics (ALLO) has received three FDA Fast Track Designations for ALLO-329, a next-generation dual-targeted CD19/CD70 allogeneic CAR T therapy. The designations cover treatments for systemic lupus erythematous (SLE), idiopathic inflammatory myopathy (IIM), and diffuse systemic sclerosis (SSc).
The company plans to initiate the Phase 1 RESOLUTION basket trial in mid-2025, with initial proof-of-concept expected by year-end 2025. The trial will evaluate ALLO-329's safety and preliminary efficacy using the proprietary Dagger® technology, which aims to reduce or eliminate lymphodepletion requirements. The study includes two lymphodepletion arms: one using cyclophosphamide alone and another without lymphodepletion.
Allogene Therapeutics (NASDAQ: ALLO) has provided Q4 and full year 2024 financial results and corporate updates. The company reported key developments across its pipeline:
Their lead program Cemacabtagene Ansegedleucel (Cema-Cel) is advancing in the pivotal Phase 2 ALPHA3 trial for first-line Large B-Cell Lymphoma, with 40 sites activated. A lymphodepletion analysis is expected mid-2025, with primary EFS data around year-end 2026.
The FDA cleared ALLO-329's IND for autoimmune diseases, with trial initiation planned for mid-2025. ALLO-316 for renal cell carcinoma completed Phase 1b enrollment with data expected mid-2025.
Financial highlights: Q4 2024 net loss was $59.9 million ($0.28 per share). Full year 2024 net loss was $257.6 million ($1.32 per share). Cash position stands at $373.1 million as of December 31, 2024, with runway into second half of 2026.
Allogene Therapeutics (ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune disease, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after market close.
The company will host a conference call and webcast at 2:00 PM PT/5:00 PM ET on the same day. Investors can access the listen-only webcast through Allogene's website, with a replay available for approximately 30 days. Those wishing to participate in the Q&A session must register separately to receive a personal PIN for call access.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech company focused on developing allogeneic CAR T (AlloCAR T™) therapies for cancer and autoimmune diseases, has announced its upcoming participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 8:20 AM PT/11:50 AM ET.
The company will make webcasts available on their website www.allogene.com under the Investors tab, with replays accessible for approximately 30 days after the event.
Allogene Therapeutics (NASDAQ: ALLO) has expanded its strategic partnership with Foresight Diagnostics to develop minimal residual disease (MRD) assay as a companion diagnostic for cemacabtagene ansegedleucel (cema-cel) treatment in large B-cell lymphoma (LBCL) patients across Europe, UK, Canada, and Australia.
The collaboration focuses on using Foresight's CLARITY™ assay to identify MRD-positive patients in the pivotal ALPHA3 trial, where cema-cel is being studied as a first-line treatment. The assay will help identify high-risk patients who achieve remission but remain MRD positive, offering them a one-time consolidation dose of cema-cel to prevent disease recurrence.
Under the agreement, Allogene will invest $37.3 million for MRD assay development, milestone payments for regulatory submissions, and clinical sample testing. Both companies will work towards obtaining regulatory approvals for their respective products.
Allogene Therapeutics published Phase 1 ALPHA/ALPHA2 trial results for cemacabtagene ansegedleucel (cema-cel) in treating relapsed/refractory large B-cell lymphoma. The study demonstrated significant efficacy with 58% overall response rate and 42% complete response rate across all patients, improving to 67% and 58% respectively with the pivotal study regimen.
Key highlights include a median duration of response of 23.1 months among complete responders, with median overall survival not reached. The treatment showed a manageable safety profile with no graft-versus-host disease, neurotoxicity syndrome, or high-grade cytokine release syndrome. Notably, the median time to treatment was just two days from enrollment.
The study revealed 100% complete response rates in patients with low disease burden, supporting the ongoing ALPHA3 trial which evaluates cema-cel as a first-line consolidation therapy. This represents the largest dataset of LBCL patients treated with an allogeneic CAR T product, with minimum two-year follow-up.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12, at 12:20 PM PT/3:20 PM ET. Webcasts will be available on the company's website under the Investors tab, with replays accessible for approximately 30 days after the event.
Allogene Therapeutics (Nasdaq: ALLO) has announced the promotion of Benjamin M. Beneski to Senior Vice President and Chief Technical Officer (CTO). He succeeds Tim Moore, who will step down at the end of February after two years with the company. Beneski, who joined Allogene in 2019, will oversee technical operations and advance the company's allogeneic cell therapy programs.
Beneski's experience includes leading the design and construction of Cell Forge 1, the company's manufacturing facility, and serving as Vice President of Manufacturing and Vice President of Product Development and Manufacturing. His career spans over 20 years in biologics manufacturing, with previous roles at Vir Biotechnology and Amgen.
Allogene Therapeutics (ALLO) has received FDA clearance for its Investigational New Drug (IND) application for ALLO-329, a dual-targeted CD19/CD70 allogeneic CAR T product designed for autoimmune diseases. The company plans to initiate the Phase 1 RESOLUTION basket trial in mid-2025, targeting systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies, and systemic sclerosis.
The trial will utilize Allogene's proprietary Dagger® technology to enhance CAR T cell expansion and prevent rejection, featuring two lymphodepletion arms: one using cyclophosphamide alone and another without lymphodepletion. ALLO-329's dual-targeting design against CD19+ B-cells and CD70+ activated T-cells aims to address immune dysregulation in autoimmune diseases. The company's manufacturing capacity can potentially produce up to 60,000 doses annually.
